

September 26, 2011
AnGes MG, Inc.

Second Prize in the Year 2011 Intellectual Property Award by Osaka Prefecture
- HGF (Hepatocyte Growth Factor) Gene Therapy against Peripheral Arterial Obstruction -

AnGes MG, Inc. is pleased to announce that HGF (hepatocyte growth factor) gene therapy against peripheral arterial obstruction was awarded second prize in the year 2011 Intellectual Property Award, sponsored by Osaka prefecture.

Osaka prefecture website:

<http://www.pref.osaka.jp/hodo/index.php?site=fumin&pageld=8176>

Osaka prefecture is sponsoring Intellectual Property Award for the below purpose (excerpted from the application guideline and roughly translated as):

“Osaka prefecture supports small and medium sized companies within the prefecture with product branding through promotion by awarding their business using patent rights owned by research institutions such as university in and outside of Osaka prefecture. Through awarded companies’ missionary outreach (promotion and awareness raising activities in the form of lectures on intellectual property, etc.), value of intellectual property will become widely known. Also, collaboration with academic and other research institutions and the use of intellectual assets owned by small and medium sized companies will be promoted.”

AnGes MG submitted an award entry with its main project, “HGF (hepatocyte growth factor) gene therapy against peripheral arterial obstruction” and was evaluated mainly on such aspects as “technology,” “impact (market size/share, prominence, overseas development, etc.),” “corporate strategy,” “social contribution” and “contribution after award.” Osaka prefecture took overall needs for support into considerations, and AnGes MG was awarded second prize.

AnGes MG is currently planning a global phase III clinical trial on HGF gene therapy for peripheral arterial obstruction in the U.S. and Europe. The review of study protocol by the U.S. National Institutes of Health has completed and AnGes MG is now moving forward with preparation to start the trial.

President and Chief Executive Officer, Ei Yamada commented as “We greatly appreciate being awarded the second prize as it shows that Osaka prefecture kindly understands and supports our business plan.”

This trend will have no effect on the business performance for the fiscal year of 2011.

###